Stem Cell Research & Therapy

4.2k papers and 129.0k indexed citations i.

About

The 4.2k papers published in Stem Cell Research & Therapy in the last decades have received a total of 129.0k indexed citations. Papers published in Stem Cell Research & Therapy usually cover Molecular Biology (2.0k papers), Genetics (1.8k papers) and Surgery (1.2k papers) specifically the topics of Mesenchymal stem cell research (1.8k papers), Tissue Engineering and Regenerative Medicine (670 papers) and Pluripotent Stem Cells Research (551 papers). The most active scholars publishing in Stem Cell Research & Therapy are Gang Li, Rocky S. Tuan, Zhongchao Han, Patrícia R. M. Rocco and Zongjin Li.

In The Last Decade

Fields of papers published in Stem Cell Research & Therapy

Since Specialization
EngineeringComputer SciencePhysics and AstronomyMathematicsEarth and Planetary SciencesEnergyEnvironmental ScienceMaterials ScienceChemical EngineeringChemistryAgricultural and Biological SciencesVeterinaryDecision SciencesArts and HumanitiesBusiness, Management and AccountingSocial SciencesPsychologyEconomics, Econometrics and FinanceHealth ProfessionsDentistryMedicineBiochemistry, Genetics and Molecular BiologyNeuroscienceNursingImmunology and MicrobiologyPharmacology, Toxicology and Pharmaceutics

This network shows the specialization of papers published in Stem Cell Research & Therapy. Nodes represent fields, and links connect fields that are likely to share authors.

Countries where authors publish in Stem Cell Research & Therapy

Since Specialization
Total citations of papers

This map shows the geographic distribution of research published in Stem Cell Research & Therapy. It shows the number of citations received by papers published by authors working in each country. You can also color the map by specialization and compare the number of papers published in Stem Cell Research & Therapy with the expected number of papers based on a country's size and research output (numbers larger than one mean the country's share of papers is larger than expected).

Rankless by CCL
2025